Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Oneness Biotech Co's ROE % or its related term are showing as below:
LUX:ONEA'
s ROE % Range Over the Past 10 Years
Min: -10.75 Med: -7.05 Max: 2.51
Current: -9.47
During the past 13 years, Oneness Biotech Co's highest ROE % was 2.51%. The lowest was -10.75%. And the median was -7.05%.
LUX:ONEA's ROE % is ranked better than 69.82% of 1249
companies
in the Biotechnology industry
Industry Median: -38.61
vs LUX:ONEA: -9.47
Oneness Biotech Co (LUX:ONEA) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Oneness Biotech Co ROE % Related Terms
Oneness Biotech Co ROE % Historical Data
* Premium members only.
The historical data trend for Oneness Biotech Co's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Oneness Biotech Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oneness Biotech Co ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oneness Biotech Co's ROE % distribution charts can be found below:
* The bar in red indicates where Oneness Biotech Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Oneness Biotech Co (LUX:ONEA) has a ROE % of -1.32% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Oneness Biotech Co and its competitors. According to the industry distribution chart, Oneness Biotech Co ranks #377 out of 1249 companies in the Biotechnology industry, placing it in the top 30.2%.
Is Oneness Biotech Co's ROE % too high?
Oneness Biotech Co's current ROE % is -1.32%. Based on the distribution chart, Oneness Biotech Co ranks #377 out of 1249 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Oneness Biotech Co has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Oneness Biotech Co's ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oneness Biotech Co ranks #377 out of 1249 companies for ROE %. This puts Oneness Biotech Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Oneness Biotech Co and its competitors. Oneness Biotech Co's current ROE % is -1.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oneness Biotech Co stock overvalued right now?
Oneness Biotech Co (LUX:ONEA) has a current ROE % of -1.32%. The stock's GF Value™ is $35.65, compared to a current price of $23.60 — trading 33.8% below its estimated fair value. The current ROE % is -1.32%. Oneness Biotech Co's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Oneness Biotech Co (LUX:ONEA), the current ROE % is -1.32% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oneness Biotech Co (LUX:ONEA) Overvalued in 2026?
Based on GuruFocus' analysis, Oneness Biotech Co stock appears to be undervalued.
The current stock price of $23.60 is trading 33.8% below its estimated GF Value™ of $35.65.
Key valuation signals for LUX:ONEA:
ROE %: -1.32%
GF Value™: $35.65 vs. price of $23.60 (33.8% below fair value)
No single metric tells the full story. See the LUX:ONEA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oneness Biotech Co Ltd is engaged in the research and development of new drugs, the sale of pharmaceutical products and health products, and other related businesses. It focuses on developing drugs for the treatment of chronic skin and immune diseases. The Group's product portfolio comprises FESPIXON cream, for the treatment of diabetic foot ulcers, and Bonvadis, a wound care medical device. It also has various other product candidates in its development pipeline, such as FB825, FB704A, SNS812, SNS851, and others. The Group operates in the following reportable segments: New drug research and development, which derives maximum revenue, and the Agricultural products cultivation and organic food segment.
59GF Score
Get the complete analysis for LUX:ONEA
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUX:ONEA has been successfully added to your 
